New oral drug could replace injections for kidney anemia
NCT ID NCT07565701
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a gradual switch from the injected drug Epogen to an oral medication called vadadustat for people with anemia who are on dialysis. The goal is to see if patients can stay on vadadustat long-term without stomach issues or drops in red blood cell levels. About 100 adults will take part, and the main measure is how many remain on vadadustat after 20 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vadadustat (oral drug) and epoetin alfa (Epogen)
- What this could lead to
- If successful, this could offer a more convenient oral option for managing anemia in dialysis patients, potentially with fewer side effects.
- What could go wrong
- This is a small, early-phase trial focused on tolerability, not long-term outcomes. The drug may still cause gastrointestinal issues or fail to maintain stable hemoglobin levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill vs. a shot: which eases Kidney-Related anemia better?
- Can a pill replace EPO shots for anemia in kidney disease?
- New pill could help dialysis patients fight anemia without needles
- New pill could replace needles for anemia in dialysis patients
- New pill could help kidney patients fight anemia without needles
- New anemia pill challenges standard shot for dialysis patients